Furkan AYAZ, Qadar Ahmed ISSE, Rusmeenee KHEEREE, Ronak Haj ERSAN, Öztekin ALGÜL

Immunomodulatory and immunostimulatory effects of some bisbenzoxazole derivatives on lipopolysaccharide stimulated mammalian macrophages

Benzoxazoles and their derivatives have exerted anti-cancer and anti-inflammatory (immunomodulatory)potential due to their anti-proliferative effect on the cells. These molecules are DNA basebioisosteres, therefore, theirmechanism of action could be by mimicking the structures of the DNA bases and halting the DNA polymerizationprocesses. Based on their anti-proliferative effect, in our study we aimed to decipher the potential anti-inflammatoryactivities of unique bisbenzoxazole derivatives in vitro on mammalian macrophages. Being able to manipulate theinflammatory function of macrophages would enable the regulation of the immune response against danger stimuli.This would enable us better prognosis against different types of the diseases ranging from autoimmune disorders tocancer. Our results support the stark anti-inflammatory potential of bisbenzoxazole derivatives RHE 241 and RHE 248in vitro on the LPS activated mammalian macrophages. After further delineation of their mechanism of action in vitroand their in vivo potency, these molecules could be utilized as potent anti-inflammatory medicines.

PDF

___

[1] Arango DG, Descoteaux A. Macrophage cytokines: Involvement in ımmunity and ınfectious diseases. Front Immuno. 2014; 491(5): 491-502. [CrossRef]
[2] Murray RZ, Stow JL. Cytokine secretion in macrophages: SNAREs, Rabs, and membrane trafficking. Front Immunol. 2014; 5: 538-546. [CrossRef]
[3] Kawagishi C, Kurosaka K, Watanabe N, Kobayashi Y. Cytokine production by macrophages in association with phagocytosis of etoposide-treated P388 cells in vitro and in vivo. Biochim Biophys Acta. 2001; 1541(3): 221-230. [CrossRef]
[4] Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother. 1994; 48(10): 445-453. [CrossRef]
[5] Scull CM, Hays WD, Fischer TH. Macrophage proinflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflam. 2010; 7(53): 1-9. [CrossRef]
[6] Berghaus LJ, Moore JN, Hurley DJ, Vandenplas ML, Fortes BP, Wolfert MA, Boons GJ. Innate immune responses of primary murine macrophage-lineage cells and RAW 264.7 cells to ligands of Toll-like receptors 2, 3, and 4. Comp Immunol Microbiol Infect Dis. 2010; 33(5): 443-454. [CrossRef]
[7] Schmitz F, Mages J, Heit A, Lang R, Wagner H. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: From expression profiling to a model of TLR signaling. Eur J Immunol. 2004; 34(10): 2863- 2873. [CrossRef]
[8] Soromou LW, Zhang Z, Li R, Chen N, Guo W, Huo M, Guan S, Lu J, Deng X. Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin. Molecules. 2012; 17(3): 3574-3585. [CrossRef]
[9] Gasparini C, Foxwell BM, Feldmann M. RelB/p50 regulates TNF production in LPS-stimulated dendritic cells and macrophages.Cytokine. 2013; 61(3): 736-740. [CrossRef]
[10] Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20(2): 87–103.
[11] Lopez CG, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011; 22(4): 189–195. [CrossRef]
[12] Manderson AP, Kay JG, Hammond LA, Brown DL, Stow JL. Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFα. J Cell Biol. 2007; 178(1): 57-69. [CrossRef]
[13] Grossi G, Di BM, Roma G, Ballabeni V, Tognolini M, Barocelli E. 1,8-Naphthyridines v. novel N-substituted 5-amino- N,N-diethyl-9- isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity. Eur J Med Chem. 2005; 40(2): 155–165. [CrossRef]
[14] Dianzani C, Collino M, Gallicchio M, Di Braccio M, Roma G, Fantozzi R. Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8] naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. J Inflamm. 2006; 3(1): 4-13. [CrossRef]
[15] Broide DH. Immunomodulation of Allergic Disease. Annu Rev Med. 2009; 60: 279-291. [CrossRef]
[16] Iwalewa EO, McGaw LJ, Naidoo V, Eloff JN. Inflammation: the foundation of diseases and disorders. A review of phytomedicines of South African origin used to treat pain and inflammatory condition. Afr J Biotechnol. 2007; 6(25): 2868-2885. [CrossRef]
[17] Ayaz F. Ruthenium pyridyl thiocyanate complex increased the production of pro-inflammatory TNFα and IL1β cytokines by the LPS stimulated mammalian macrophages in vitro. Mol Biol Rep. 2018; 45(6): 2307-2312. [CrossRef]
[18] Ayaz F, Yuzer A, Ince M. Immunostimulatory effect of Zinc Phthalocyanine derivatives on macrophages based on the pro-inflammatory TNFα and IL1β cytokine production levels. Toxicol in Vitro. 2018; 53: 172-177. [CrossRef]
[19] Hancock REW, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012; 10: 243-254. [CrossRef]
[20] Kaufmann T,Simon HU. Targeting disease by immunomodulation. Cell Death Differ. 2015; 22(2): 185–186. [CrossRef]
[21] Julier Z, Park AJ, Briquez PS, Martino MM. Promoting Tissue Regeneration by Modulating the Immune System. Acta Biomaterialia. 2017; 53: 13-28. [CrossRef]
[22] Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016; 13(5): 273–290. [CrossRef]
[23] Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007; 19(2): 209-216. [CrossRef]
[24] Daniel CS, Ira M. Oncology meets immunity. Immunity, 2013; 39(1): 1-10. [CrossRef]
[25] Guevara PJA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: Studies with melanoma, advances in cancer research. Academic Press, 2003; 90: 157-177. [CrossRef]
[26] Valdés RR, Benítez AA. Nutrition and immunity in cancer. Br J Nutr. 2007; 98(S1): 127-132. [CrossRef]
[27] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6): 883–899. [CrossRef]
[28] Rakoff N S. Why Cancer and Inflammation? Yale J Biol Med. 2006; 79(3-4): 123-130.
[29] Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860-867.
[30] Algul O, Kaessler A, Apcin Y, Yilmaz A, Jose J. Comparative studies on conventional and microwave synthesis of some benzimidazole, benzothiazole and indole derivatives and testing on inhibition of hyaluronidase. Molecules, 2008; 13(4): 736-748.
[31] Ayaz F, Kheeree R, Isse Q, Ersan R, Algul O. DNA Base Bioisosteres, Bis-benzoxazoles, Exert anti-proliferative effect on human prostate and breast cancer cells. JOTSCA. 2018, 5(3): 1145-1152. [CrossRef]
[32] Kaessler A, Algul O, Jose J. A microplate based screening of benzimidazole derivatives on hyaluronidase inhibition at pH 7 and 3.5. Lett Drug Des Discov. 2007; 4(8): 562-569. [CrossRef]
[33] Algul O, Duran N. Activity of bisbenzimidazole derivatives against Staphylococcus epidermidis. Asian J Chem. 2007; 19(4): 3145-3151.
[34] Kandeel MM, Abdelall EKA, Abd El Hamid MK, Abdelgawad MA, Philoppes JN. Synthesis and in vitro antitumor activity of new benzothiazole and benzoxazole derivatives. J Chem Pharm Res. 2013; 5(8): 16-21.
[35] Shitha G, Amma VK, Kamala B, Babu G, Biju CR. In-silico docking investigation, synthesis and in vitro anticancer study of benzoxazole derivatives. J Drug Deliv. Technol. 2014; 4(6): 122-126. [CrossRef]
[36] Hedidi M, Bentabed AG, Derdour A, Roisnel T, Dorcet V, Chevallier F, Picot L, Thiery V, Mongin F. Synthesis of C,N'-linked bis-heterocycles using a deprotometalation-iodination-N-arylation sequence and evaluation of their antiproliferative activity in melanoma cells. Bioorg Med Chem. 2014; 22(13): 3498-3507. [CrossRef]
[37] Gülcan HO, Ünlü S, Banoğlu E, Şahin MF, Küpeli E, Yeşilada E. Synthesis of new 4-(5-Chloro-2-oxo-3H-benzoxazol- 3-yl)butanamide derivatives and their analgesic and anti-inflammatory properties. Turk J Chem. 2003; 27: 467-476.
[38] Koksal M, Gokhan N, Kupeli E, Erdogan H. Analgesic and antiinflammatory activities of some new mannich bases of 5-nitro-2-benzoxazolinones. Arch Pharm Res. 2007; 30(4): 419-424.
[39] Potashman M, Bready J, Coxon A, DeMelfi T. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J Med Chem. 2007; 50(18): 4351–4373. [CrossRef]
[40] Xue C, Rafalski M, Roderick J, Eyermann CJ, Mousa S, Olson RE, DeGrado WF. Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorg Med Chem Let. 1996; 6(3): 339-344. [CrossRef]
[41] Sun LQ, Chen J, Takaki K, Johnson G. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg Med Chem Lett. 2004; 14(5): 1197-2000. [CrossRef]
[42] Kumar JMR, Reynolds MB, Kerwin SM. Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem. 2002; 10(12): 3997-4004.
[43] Klimesova V, Koci JK, Waisser J, Kaustova U. Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents. Eur J Med Chem. 2009; 44(5): 2286-93. [CrossRef]
[44] Kakkar S, Tahlan S, Lim SM, Ramasamy K, Mani V, Shah SAA, Narasimhan B. Benzoxazole derivatives: design, synthesis and biological evaluation. Chem Cent J. 2018; 12(1):92. [CrossRef]
[45] Chandni J, Neeru C, Meena N, Gita S. Synthesis and Biological activity of organophosphates phenoxy derivatives derived from 2-mercapto benzoxazole. Phosphorus Sulfur Silicon Relat Elem. 2014; 189(11): 1699-1705. [CrossRef]